Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ABBV-101 study in relapsed/refractory B-cell malignancies
jRCT2031230249Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of ABBV-101 in B-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL) and 6 more (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events, Change in laboratory parameters and 2 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
ABBV-101
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2031230249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230249.